1. 920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. (23rd October 2018) Authors: Loriot, Y; Necchi, A; Park, S H; Huddart, R A; Burgess, E; Zhong, B; Santiago-Walker, A; Little, S; Roccia, T; De Porre, P; Siefker-Radtke, A O Journal: Annals of oncology Issue: Volume 29(2018)Supplement 8 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 932PHyperphosphatemia due to erdafitinib (a pan-FGFR Inhibitor) and anti-tumour activity among patients (Pts) with advanced urothelial carcinoma (UC). (1st October 2019) Authors: Tagawa, S; Siefker-Radtke, A; Dosne, A -G; Zhong, B; Qi, K; Shalaby, W; O'Hagan, A; De Porre, P; Mahadevia, P; Loriot, Y Journal: Annals of oncology Issue: Volume 30(2019)Supplement 5 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A blockchain-based framework for supporting BIM-based building code compliance checking workflow. Issue 1 (January 2022) Authors: Gao, H; Zhong, B Journal: IOP conference series Issue: Volume 1218:Issue 1(2022) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗